Banking on iPSC- Is it Doable and is it Worthwhile

Abstract

The discovery of induced pluripotent stem cells (iPSCs) and concurrent development of protocols for their cell-type specific differentiation have revolutionized studies of diseases and raised the possibility that personalized medicine may be achievable. Realizing the full potential of iPSC will require addressing the challenges inherent in obtaining appropriate cells for millions of individuals while meeting the regulatory requirements of delivering therapy and keeping costs affordable. Critical to making PSC based cell therapy widely accessible is determining which mode of cell collection, storage and distribution, will work. In this manuscript we suggest that moderate sized bank where a diverse set of lines carrying different combinations of commonly present HLA alleles are banked and differentiated cells are made available to matched recipients as need dictates may be a solution. We discuss the issues related to developing such a bank and how it could be constructed and propose a bank of selected HLA phenotypes from carefully screened healthy individuals as a solution to delivering personalized medicine.

Tissue Engineering and Regenerative Medicine 2015: A Year in Review

“…These banks could adopt several models for matching haplotypes of human leukocyte antigens (HLAs), which are described briefly below. [30][31][32][33] One model would account for patientspecific iPS cells, which would be expected to have only the relatively weak antigenicity that was detailed in the previous section. While providing the best HLA match to the patient, this method suffers from the late onset for therapy development.…”

Ips Progression a Decade Devoted

“…Blood Disorders such as sickle cell anemia [74], fanconis anemia [75], hemophilia A [76] and β-thalassemia [77]. Genetic diseases: Downs syndrome [78], familial dysautonomia [79] and Huntington's disorder [80].…”

Expression of HLA-DR genes in gliomas: correlation with clinicopathological features and prognosis

“…This finding was unanticipated and piqued our interest. As HLA-DR has been known as the antigen which is most responsible for graft loss during the first 6 months, whereas HLA-B is more important during the first 2 years, and HLA-A is associated with long-term survival [21]. Overexpression of these molecules is supposed to increase tumor immunogenicity, and thus slow or even prevent tumor growth.…”